EMA explains how to determine API "strength" in a drug name
This article was originally published in SRA
Executive Summary
The European Medicines Agency has adopted new recommendations on how to express the strength of an active pharmaceutical ingredient in a medicine’s name1. The recommendations will apply to all new marketing authorisation applications in the centralised procedure as of 1 March.